Related Experiment Video
Updated: Apr 8, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens
Ladislava Vymětalová1, Vladimír Kryštof1
1Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University and Institute of Experimental Botany AS CR, Šlechtitelů 11, CZ-78371, Olomouc, Czech Republic.
Abstract:
Developments in genetic and genomic technology have produced vast quantities of data that are gradually yielding new insights into fundamental cellular and molecular processes. In particular, they have revealed some differences between normal and transformed cells that could potentially be exploited to develop targeted, personalized cancer therapies with unprecedented efficiencies. This review summarizes recent findings from synthetic lethality (SL) screens against cyclin-dependent kinases (CDKs) that can be targeted with small molecule kinase inhibitors. SL screens can be used to identify cancers sensitive to CDK inhibitors. Several SL partners of specific CDKs have been identified, including MYC, K-Ras, VHL, PI3K, and PARP, all of which are discussed in the review. CDK inhibitors have been in clinical trials for nearly 20 years and it has become clear that effective therapy using these compounds will require careful selection of patients with respect to the specific molecular phenotype of their disease.
Insights
Synthetic lethality screens identify cancer vulnerabilities to cyclin-dependent kinase (CDK) inhibitors. Targeting CDK inhibitors requires careful patient selection based on molecular profiles for effective cancer therapy.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Genetic and genomic advancements offer insights into cellular processes.
- Differences between normal and transformed cells can guide targeted cancer therapies.
Purpose of the Study:
- Review findings from synthetic lethality (SL) screens targeting cyclin-dependent kinases (CDKs).
- Identify cancers sensitive to CDK inhibitors and potential therapeutic targets.
Main Methods:
- Utilized synthetic lethality (SL) screens to identify drug targets.
- Analyzed genetic and genomic data for cancer-specific vulnerabilities.
Main Results:
- Identified several SL partners for specific CDKs, including MYC, K-Ras, VHL, PI3K, and PARP.
- SL screens can pinpoint cancers susceptible to CDK inhibition.
Conclusions:
- Effective CDK inhibitor therapy necessitates patient stratification based on molecular phenotype.
- Targeted cancer therapies show potential for increased efficiency.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Related Concept Videos
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...